Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02819271 | A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers | PHASE1 | COMPLETED | 80 | — | — | Feb 1, 2014 | Apr 1, 2014 | Jan 23, 2017 | - | — |
| Arm | Type | Description |
|---|---|---|
| CXL-1427 (BMS-986231) | EXPERIMENTAL | Experimental |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| CXL-1427 Ascending Dose | DRUG | - |
| Placebo | OTHER | - |
| CXL-1427 Descending Dose | DRUG | - |
Inclusion Criteria: * No evidence of any acute or chronic health disorder * Not have taken any prescription medication within 15 days of study entry * Not have taken any over-the-counter medication or herbal/vitamin supplement within 3 days of study entry * Not have not have any dietary restriction...